WebJul 25, 2024 · To assess the potential of early control of systemic disease with multiagent perioperative chemotherapy, the randomized phase II SWOG S1505 trial compared modified FOLFIRINOX (fluorouracil [5-FU] at 2,400 mg/m 2 over 46 hours, irinotecan at 180 mg/m 2, and oxaliplatin at 86 mg/m 2) to gemcitabine (1,000 mg/m 2) plus nab-paclitaxel at 125 … WebApr 19, 2024 · This is a Joint SWOG & NRG Oncology FDA registration-intent trial. NRG Oncology institutions can credit NRG for their case accrual. NRG Canadian member sites must credit the Canadian Clinical Trials Group (CCTG). SWOG Study Chair: Parminder Singh, M.D. Patient Population. Patients with muscle invasive bladder cancer (MIBC) (T2 …
Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol …
WebSWOG 1827: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation ... (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) … WebThis document contains current information related to expectations for protocol compliance, documentation practices, and consenting issues for those participating on … marney hamilton
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine …
WebThe purpose of these guidelines is to provide information related to expectations for protocol compliance, documentation practices and consenting issues for SWOG studies … WebMay 11, 2014 · Purpose The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknown. S0809 was designed to estimate 2-year survival (overall and after R0 or R1 resection), pattern of relapse, and toxicity in patients treated with this adjuvant regimen. Patients and Methods Eligibility … WebJul 6, 2024 · Herbst RS, Gandara DR, Hirsch FR, et al. Lung Master Protocol (Lung-MAP) — a biomarker-driven protocol for accelerating development of therapies for squamous cell … marney goldstein md plantation fl